Clinical Trial

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2024-05-15; most recent amendment 2026-02-20.
Status change: Recruiting → Active, Not Recruiting 2026-02-20
Status change: Not Yet Recruiting → Recruiting 2024-11-21
Trial Details
NCT Number NCT06422884
Lead Sponsor Endeavor Biomedicines, Inc.
Conditions Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
Enrollment 213 participants
Start Date 2024-11-15
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-02-24